Navigation Links
China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory
Date:12/15/2009

HARBIN, China, Dec. 15 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company has 30 medicines that will be included in the 2009 Edition of the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Medicine Directory.

The 30 medicines treat a variety of common ailments and make up 17% of the Company's revenues for the first nine months of 2009. Nine of the medicines, including Salbutamol, Compound Sulfamethoxazole Tablets, Nitrofurantoin Enteric-coated Tablets, Amidopyrine and Phenacetin Compound Tablets, Isatis Root Granules, Pulse-activating Decoction, Compound Salvia Tablets, Guanxinsuhe Capsules, and Antibiotic and Liver Cholaneresis Soothing Tablets, are Category A medicines. Consumption of Category A drugs will be fully reimbursed by the national basic medical insurance system.

The 2009 Edition Directory includes a total of 2,151 medicines. There are 1,164 Western drugs in the Directory, including 349 Category A medicines, 791 Category B medicines, 20 restricted work injury insurance agents, and four maternity insurance agents. In addition, there are 987 Chinese medicines, including 154 Category A medicines and 833 Category B medicines.

"We are excited to have 30 medicines included in the 2009 Edition Directory, which we expect to result in increased sales volumes for these products as pharmacies in China make them widely available to meet demand from patients," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "Few other pharmaceutical companies in China have accomplished this goal, and it further demonstrates the market potential for our rich product portfolio."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the inclusion of the Company's drugs in the 2009 Edition of National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Medicine Directory. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-0451-5399-4069
     Email: stanleyhao@cski.com.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE China Sky One Medical, Inc.


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Biologic Products to Ring NASDAQ Opening Bell
2. Simcere Announces 105 Drugs Included in Chinas National Drug Reimbursement List
3. Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit
4. Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies
5. China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia
6. China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List
7. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
8. China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information
9. Niusule Expands Geographic Footprint in China
10. China Pharma Holdings, Inc. to Present at Brean Murray China Growth Conference
11. China Business Knowledge Launches “China Prospects Forum” -- Dec. 9, 2009, New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... CALIFORNIA (PRWEB) , ... October 10, 2017 , ... ... technological innovation and business process optimization firm for the life sciences and healthcare ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation for ...
Breaking Biology Technology:
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):